

Supporting you and your patients throughout their ZYMFENTRA treatment journey

There are 3 options to enroll in the Celltrion CONNECT[®] program:

Option 1: Online Portal

- Visit the Celltrion Connect website: **CelltrionConnect.com/ZYMFENTRA**
- Set up an account for your office*
- Enter the Provider Portal to complete and submit the enrollment form online

Option 2: Enrollment Form

- Visit the Celltrion Connect website: **CelltrionConnect.com/ZYMFENTRA**
- Download and complete the enrollment form and then fax to **833-912-3707**

Option 3: ePrescription

- In your EMR, select **Phyz** via the pharmacy drop-down menu (NCPDP: 5928809)
- Search for **ZYMFENTRA** and provide the required information
- Track the status and manage refills in the healthcare provider portal

*This is a simple two-part step of enrolling your practice, receiving validation approval within 24 hours, and then enrolling the prescribers affiliated with your office.

Send supporting documentation through your EMR or by fax to 833-912-3707:

Clinical notes • Previous therapies • Insurance information • ICD-10 code for an approved indication



Scan the QR Code or visit
CelltrionConnect.com/ZYMFENTRA
to enroll your patient today!



Call Celltrion CONNECT at
877-812-6662 for additional
information on enrolling

Once your patient is enrolled, Celltrion CONNECT will:



Verify Insurance Coverage

- Confirm coverage for ZYMFENTRA
- Confirm coverage for intravenous (IV) infliximab, if you have requested this service



Assist with Prior Authorization (PA) and Appeals Support

- Help you determine your patient's plan-specific requirements and submission protocols
- When submitting a PA, collect the information below along with other plan requirements necessary to obtain a PA decision:
 - ✓ Patient diagnosis (ICD-10) code
 - ✓ Letter of medical necessity to explain the need for ZYMFENTRA
 - ✓ Induction dose of infliximab details (product name and dates administered)
 - ✓ Previously used conventional treatments

CELLTRION
inFORM

ACCESS SOLUTIONS FOR PATIENTS & PRACTICES

Celltrion provides a dedicated field reimbursement manager who can support your office and answer questions: **877-812-6662**

Please see full Prescribing Information, including BOXED WARNING by scanning the QR code on the reverse.

The Celltrion CONNECT[®] Case Coordinator will:



Determine Eligibility for Financial Assistance

Commercially insured patients may be eligible to receive assistance through the Celltrion CARES[®] Co-pay Assistance Program

- Learn more and view complete program rules at [CelltrionCARES.com](https://www.CelltrionCARES.com)

Celltrion may provide ZYMFENTRA to eligible* patients experiencing a delay obtaining coverage for ZYMFENTRA:

- Eligibility is restricted to patients with commercial insurance who have been prescribed ZYMFENTRA for an on-label indication
- Eligibility for continued participation will be verified periodically, and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria, including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan

ZYMFENTRA Patient Assistance Program

- Patients who are uninsured may be eligible to receive ZYMFENTRA at no cost
- ZYMFENTRA Patient Assistance Program eligibility criteria, terms and conditions apply

Eligible[†] patients
may pay as little as

\$0

for each dose



Connect Your Patients to Nursing Support

The Celltrion CONNECT Case Coordinator can pair your patient with a dedicated Nurse Connector[™], who can assist them in adhering to their prescribed treatment regimen[‡]

Nurse Connectors can help provide patients with education on ZYMFENTRA and their diagnosis

- Support in the transition from IV infliximab to ZYMFENTRA
- Supplemental injection training on how to use their injection device
- Product and disease state education
- Tools and resources to track injection site rotation and dosing schedule



You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including **BOXED WARNING** by scanning the QR code.

EMR, electronic medical record; FDA, U.S. Food & Drug Administration; ICD-10, International Classification of Diseases, 10th Revision; ICD-10, International Classification of Diseases, 10th Revision, Clinical Modification; NCPDP, National Council for Prescription Drug Programs.

*Celltrion may provide ZYMFENTRA to eligible patients including those with commercial insurance experiencing delays or a gap in coverage of ZYMFENTRA. Eligible patients must have been prescribed ZYMFENTRA for an FDA-approved indication and their participation is in no way contingent on any requirement or obligation to purchase ZYMFENTRA or any other Celltrion product or service at any time. Patients who are covered in whole or part through a state or federal healthcare program including but not limited to Medicare Medicaid Medigap CHAMPUS TRICARE Veterans Affairs or Department of Defense are not eligible. Eligibility for continued participation will be verified periodically and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan. This offering will end on December 31, 2025. Void where prohibited or restricted by law and Celltrion reserves the right to rescind revoke or amend the terms and conditions at any time without notice.

[†]Please see full terms and conditions for Celltrion CARES at www.celltrionconnect.com/zymfentra/co-pay-assistance.

[‡]Participation in the Nurse Connector program is voluntary. Patients can opt out of this service at any time. Nurse Connectors will not offer medical advice and will always refer the patient back to the prescriber for any questions specific to their treatment.

Celltrion product and service names mentioned are the respective trademarks of Celltrion Inc. and Celltrion Holdings, Co., Ltd., used under license by Celltrion USA, Inc.
© Celltrion USA, Inc. 2025 US-ZYM-24-00074v2 03/25